Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, shares insights into the data from cohort G of the MagnetisMM-6 trial (NCT05623020), which is comparing elranatamab, daratumumab, plus lenalidomide (EDR) to daratumumab in combination with lenalidomide and dexamethasone (DRd) in transplant-ineligible patients with newly diagnosed multiple myeloma (MM). In this cohort treated with EDR, encouraging safety and efficacy were observed, highlighting the potential of this combination therapy in the frontline setting. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.